AstraZeneca Releases Positive Data From Severe Asthma Trial

AstraZeneca’s benralizumab met its primary endpoint in two Phase 3 studies for asthma.

The company’s first biologic in its respiratory portfolio, benralizumab significantly reduced the asthma exacerbation rate compared to placebo.

The company plans to submit the candidate to U.S. and EU regulators in the latter half of the year.